Would you move this antibody candidate forward?
Take a closer look at the sensorgram.
What appears to be a strong binder may reveal something entirely different to an experienced eye. Learn the Top 6 Blind Spots of Antibody Discovery and Development.
👉 https://t.co/1369UqJVpH
Ever wondered what happens behind the scenes at Canada’s largest privately-funded mass spec facility?
Step inside to see where we’ve sequenced over 10k antibodies using cutting-edge mass spectrometry and sequencing technology. Don’t forget to tell us what you’ll sequence next!
🚨 We're heading to #ADLM2026!
Visit booth 2546 (July 26–30) to meet Jenn, Kyle, Lindsey, Natasha & Mingjie and learn how we're converting polyclonal antibodies into recombinant polyclonals and using SPR + HDX-MS to better understand antibody binding.
📍Poster B-149
🗓️ July 29
What can we learn from 100's of successful antibody characterization campaigns?
Join our experts as they reveal the top 6 blind spots in antibody interaction studies that can contribute to failed antibody candidates in later stages of development.
📝 https://t.co/TF4R4Keaju
Every assay tells part of the story. The best lead selection decisions come from putting the pieces together.
👉See how #SPR and #HDXMS work together to provide a more complete picture of ab–ag interactions.
What complementary techniques does your team use for lead selection?
What if your best hit never made it past screening?
Our SPR Kinetic Screening with the Biacore 1K is designed to uncover interactions that less sensitive approaches can miss.
#SPR#DrugDiscovery#AntibodyDiscovery#AntibodyEngineering
From discovery to validation: what's possible when #AntibodyDiscovery, #SPR, and #HDXMS experts work together to find highly specific and diverse #AntiIdiotype antibodies?
Join us for our upcoming webinar:
📅 June 23, 2026 | 10:00 AM EST
🔗 Register: https://t.co/KjWNbqdu4P
It’s not too late to get all of your hits 🎯
Our new #SPR Kinetic Screening service on #Biacore 1K is designed to help researchers identify and rank candidates with greater confidence and detect interactions overlooked by less sensitive screening approaches.
#AntibodyDiscovery
Join us for a live webinar on June 23, where we'll explore how our integrated protein sequencing and characterization workflow can accelerate anti-idiotype discovery while generating antibodies with unmatched performance metrics.
Register: https://t.co/bdW8WCQnkp
#AntiIdiotype
Heading to ASMS 2026? Check out our poster with the latest HDX-MS data for our anti-idiotype antibody discovery workflow!
📌 Poster presented by Dominic Narang
📅 June 2, 2026
🧪Antibodies & Antibody Drug Conjugates I
#ASMS2026#ASMS#MassSpec#HDXMS#Biologics
🎬We’re live from #PEGSBoston!
You can find us at ⬇️
📍 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟭𝟴
📌 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Thursday, May 15 | "Conversion of Polyclonal Anti-Idiotypes into Characterized Recombinant Antibodies"
If you’re attending PEGS, come say hello!
#PEGSummit
Come see us at #PEGSBoston next week! ⬇️
📍Booth 318
💬Podium Presentation: May 12, 12:15 PM
📊 Poster Session: May 15, Poster C091
We’re looking forward to sharing how our REpAb platform is advancing polyclonal anti-idiotype antibody discovery.
#PEGSummit
🥳 We just celebrated our 11th anniversary!
We celebrated the only way we know how: with good food and good company (don't worry, we made sure our remote teammates felt included too 😉)
Here's to 11 years of great science and even greater people!
#CompanyAnniversary
We're presenting at #PEGSBoston!
Join Thierry as he shares how our integrated proteomics workflow enables the discovery and validation of high-quality anti-idiotype antibodies, and how characterization can uncover critical optimization opportunities you might otherwise miss.
We’re gearing up for WRIB 2026!
Connect with Jennifer Crha, our Senior Sales Manager for REpAb Antibody Discovery, and learn about our next-gen tools for antibody discovery and full suite of characterization services.
#WRIB2026
First Canadian prospective clinical study evaluating EasyM® for minimal residual disease (#MRD) monitoring in multiple myeloma (#MM) has completed patient enrollment.
📰 Full press release: https://t.co/xPU2duFGcY
@PMCancerCentre